Suzhou Highfine Biotech Co (SZSE:301393) LT-Debt-to-Total-Asset : 0.00 (As of Dec. 2024)

View and export this data going back to 2023. Start your Free Trial

What is Suzhou Highfine Biotech Co LT-Debt-to-Total-Asset?

LT Debt to Total Assets is a measurement representing the percentage of a corporation's assets that are financed with loans and financial obligations lasting more than one year. The ratio provides a general measure of the financial position of a company, including its ability to meet financial requirements for outstanding loans. It is calculated as a company's Long-Term Debt & Capital Lease Obligationdivide by its Total Assets. Suzhou Highfine Biotech Co's long-term debt to total assests ratio for the quarter that ended in Dec. 2024 was 0.00.

Suzhou Highfine Biotech Co's long-term debt to total assets ratio increased from Dec. 2023 (0.00) to Dec. 2024 (0.00). It may suggest that Suzhou Highfine Biotech Co is progressively becoming more dependent on debt to grow their business.

Suzhou Highfine Biotech Co LT-Debt-to-Total-Asset Historical Data

The historical data trend for Suzhou Highfine Biotech Co's LT-Debt-to-Total-Asset can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Suzhou Highfine Biotech Co LT-Debt-to-Total-Asset Chart

Suzhou Highfine Biotech Co Annual Data

Trend

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Dec24

LT-Debt-to-Total-Asset

Get a 7-Day Free Trial

0.01

Suzhou Highfine Biotech Co Quarterly Data
	Jun18	Dec18	Dec19	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24	Jun24	Sep24	Dec24
LT-Debt-to-Total-Asset	Get a 7-Day Free Trial															-	-	-	-	-

Suzhou Highfine Biotech Co LT-Debt-to-Total-Asset Calculation

Suzhou Highfine Biotech Co's Long-Term Debt to Total Asset Ratio for the fiscal year that ended in Dec. 2024 is calculated as

LT Debt to Total Assets (A: Dec. 2024 )	=	Long-Term Debt & Capital Lease Obligation (A: Dec. 2024 )	/	Total Assets (A: Dec. 2024 )
	=	1.602	/	2349.619
	=	0.00

Suzhou Highfine Biotech Co's Long-Term Debt to Total Asset Ratio for the quarter that ended in Dec. 2024 is calculated as

LT Debt to Total Assets (Q: Dec. 2024 )	=	Long-Term Debt & Capital Lease Obligation (Q: Dec. 2024 )	/	Total Assets (Q: Dec. 2024 )
	=	1.602	/	2349.619
	=	0.00

Suzhou Highfine Biotech Co (SZSE:301393) LT-Debt-to-Total-Asset Explanation

LT Debt to Total Asset is a measurement representing the percentage of a corporation's assets that are financed with loans and financial obligations lasting more than one year. The ratio provides a general measure of the financial position of a company, including its ability to meet financial requirements for outstanding loans. A year-over-year decrease in this metric would suggest the company is progressively becoming less dependent on debt to grow their business.

Suzhou Highfine Biotech Co LT-Debt-to-Total-Asset Related Terms

Thank you for viewing the detailed overview of Suzhou Highfine Biotech Co's LT-Debt-to-Total-Asset provided by GuruFocus.com. Please click on the following links to see related term pages.

Suzhou Highfine Biotech Co Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Suzhou Highfine Biotech Co Ltd (SZSE:301393) » Definitions » LT-Debt-to-Total-Asset

Traded in Other Exchanges

N/A

Address

No. 32 Hongxi Road, F-12 Standard Factory Building, High-tech Zone, Jiangsu Province, Suzhou, CHN, 215151

Website

https://www.highfine.com

Suzhou Highfine Biotech Co Ltd is a high-tech enterprise that provides characteristic raw materials for global pharmaceutical research and development and raw material drug production companies. The products are mainly used in the fields of peptide, nucleotide and pharmaceutical synthesis. The product range covers peptide synthesis reagents for characteristic amide bond formation, molecular building blocks, protein reagents, liposome and lipid nanoparticle pharmaceutical reagents, ionic liquids , PROTAC reagents and nucleotide reagents and other types.

Executives

Dong Sheng Jun	Directors, executives
Lu Xue Gen	Directors, executives
Lv Min Jie	Directors, executives
Xu Jie	Directors, executives

Suzhou Highfine Biotech Co Headlines

No Headlines